Merck, NanoBio team on preclinical RSV deal

Ann Arbor, MI-based NanoBio Corporation said it's teaming up with an unnamed Merck subsidiary on preclinical development of an intranasal vaccine for Respiratory Syncytial Virus (RSV). Researchers will be studying a combination of Merck's RSV antigen with NanoBio's NanoStat adjuvant technology. "RSV remains a major cause of serious lung infections in children and the elderly," said NanoBio founder and CEO James Baker, Jr. in a statement. "We look forward to working together in an effort to advance RSV vaccine research." NanoBio release

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.